U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Buscemi N, Vandermeer B, Friesen C, et al. Manifestations and Management of Chronic Insomnia in Adults. Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Jun. (Evidence Reports/Technology Assessments, No. 125.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Manifestations and Management of Chronic Insomnia in Adults

Manifestations and Management of Chronic Insomnia in Adults.

Show details

References and Included Studies

    References

    1.
    Sateia MJ, Doghramji K, Hauri P. et al. Evaluation of chronic insomnia. An American Academy of Sleep Medicine Review. Sleep. 2000;23(2):243–308. [PubMed: 10737342]
    2.
    Trans-NIH Sleep Research Coordinating Committee. 2003 National Sleep Disorders Research Plan. U.S. Department of Health and Human Services. National Institutes of Health. http://www.nhlbisupport.com/sleep/research/research-a.htm.
    3.
    National Sleep Foundation. Sleep in America Poll. Data from 1997 and 2001, 2002 sleep poll. http://www.sleepfoundation.org/img/2002SleepInAmericaPoll.pdf.
    4.
    Zorick FJ, Walsh JK. In Kryger MH, Roth T, Dement WC. Principles and Practice of Sleep Medicine. 3rd Ed. Philadelphia, PA: W.B. Saunders Co; 2000. Chapter 53, Evaluation and management of insomnia.
    5.
    Sateia MJ, Nowell P. Insomnia. Lancet. 2004;364:1959–73. [PubMed: 15567013]
    6.
    Breslau N, Roth T, Rosenthal L. et al. Sleep disturbances and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry. 1996;39:411–18. [PubMed: 8679786]
    7.
    Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry. 1997;154(10):1417–23. [PubMed: 9326825]
    8.
    Leger D, Guilleminault C, Bader G. et al. Medical and socio-professional impact of insomnia. Sleep. 2002;25(6):625–9. [PubMed: 12224841]
    9.
    Ohayon M. Epidemiological study on insomnia in the general population. Sleep. 1996;19(3 Suppl):S7–15. [PubMed: 8723370]
    10.
    Roberts RE, Shema SJ, Kaplan GA. Prospective data on sleep complaints and associated risk factors in an older cohort. Psychosom Med. 1999;61(2):188–96. [PubMed: 10204972]
    11.
    Foley DJ, Monjan A, Simonsick EM. et al. Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6,800 persons over three years. Sleep. 1999;22(Suppl 2):S366–72. [PubMed: 10394609]
    12.
    Janson C, Lindberg E, Gislason T. et al. Insomnia in men - A 10-year prospective population based study. Sleep. 2001;24(4):425–30. [PubMed: 11403527]
    13.
    Gislason T, Reynisdottir H, Kristbjarnarson H. et al. Sleep habits and sleep disturbances among the elderly--an epidemiological survey. J Int Med. 1993;234(1):31–9. [PubMed: 8326287]
    14.
    Riemann D, Voderholzer U. Primary insomnia: a risk factor to develop depression? J Affect Disord. 2003;76:255–9. [PubMed: 12943956]
    15.
    Kryger MH, Roth T, Dement WC. Principles and Practice of Sleep Medicine. 3rd Ed. Philadelphia, PA: W.B. Saunders Co; 2000.
    16.
    Walsh JK, Engelhardt CL. The direct economic costs of insomnia in the United States for 1995. Sleep. 1999;22(Suppl 2):S386–93. [PubMed: 10394612]
    17.
    Walsh JK. Clinical and socioeconomic correlates of insomnia. J Clin Psychiatry. 2004;65 Suppl 8:13–9. [PubMed: 15153063]
    18.
    Stoller MK. Economic effects of insomnia. [Review][66 refs]. Clin Ther 1994; 16(5):873–97;854. [PubMed: 7859246]
    19.
    Walsh J. Pharmacologic management of insomnia. J Clin Psychiatry. 2004;65(Supp 16):41–5. [PubMed: 15575804]
    20.
    Morin CM, Colecchi C, Stone J. et al. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. J Am Med Assoc. 1999;281(11):991–9. [PubMed: 10086433]
    21.
    Linde K, Ramirez G, Mulrow CD. et al. St John's wort for depression--an overview and meta-analysis of randomised clinical trials. Br Med J. 1996;313(7052):253–8. [PMC free article: PMC2351679] [PubMed: 8704532]
    22.
    Alderson P, Green S, Higgins JPT . MEDLINE highly sensitive search strategies for identifying reports of randomized controlled trials. Cochrane Reviewer's Handbook: 4.2.2 [March 2004]. Appendix 5b http://www​.cochrane.org​/resources/handbook/hbook.htm .
    23.
    McKibbon A, Eady A, Marks S. PDQ Evidence-based Principles and Practice. Hamilton: B.C. Decker Inc., 1999.
    24.
    Tjosvold L. Systematic Reviews Filter. ARCHE (Alberta Research Centre for Child Health Evidence) website. http://www​.ualberta.ca/ARCHE/filters​.html#srmedline.
    25.
    Loney PL, Chambers LW, Bennett KJ. et al. Critical appraisal of the health research literature: prevalence or incidence of a health problem. Chronic Dis Can. 1988;19(4):170–6. [PubMed: 10029513]
    26.
    Jadad AR, Moore RA, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12. [PubMed: 8721797]
    27.
    Schulz KF, Chalmers I, Hayes RJ. et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. J Am Med Assoc. 1995;273:408–12. [PubMed: 7823387]
    28.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88. [PubMed: 3802833]
    29.
    Cohen J. Statistical power analysis for the behavioural sciences. Academic Press, New York. 1969.
    30.
    Bailey KR. Inter-study differences: How should they influence the interpretation and analysis of results? Stat Med. 1987;6:351–8. [PubMed: 3616288]
    31.
    Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58. [PubMed: 12111919]
    32.
    Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M; Davey Smith G, and Altman DG. Systematic reviews in health care. 2nd ed. London, UK: BMJ Books; 2001.
    33.
    Light RJ, Pillemer DB. Summing up. The science of reviewing research. Cambridge, MA: Harvard University Press; 1984.
    34.
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101. [PubMed: 7786990]
    35.
    Egger M, Smith GD, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315(7109):629–34. [PMC free article: PMC2127453] [PubMed: 9310563]
    36.
    Duval S, Tweedie R. A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis. J Am Med Assoc. 2000;95(449):89–98.
    37.
    American Academy of Sleep Medicine. The International Classification of Sleep Disorders, Revised. Diagnostic and Coding Manual. Rochester, MN: American Academy of Sleep Medicine; 2001.
    38.
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association Press; 1994.
    39.
    Chesson A, Hartse K, McDowell Anderson W. et al. Practice Parameters for the Evaluation of Chronic Insomnia. An American Academy of Sleep Medicine Report. Sleep. 1999;23(2):1–5. [PubMed: 10737341]
    40.
    Edinger J, Bonnet M, Bootzin R. et al. Derivation of research diagnostic criteria for insomnia: report of an American Academy of Sleep Medicine work group. Sleep. 2004;27(8):1567–96. [PubMed: 15683149]
    41.
    American Sleep Disorders Standards of Practice Committee. Practice parameters for the use of polysomnography in the evaluation of insomnia. Sleep. 1995;18:55–7. [PubMed: 7761744]
    42.
    American Sleep Disorders Standards of Practice Committee. Practice parameters for the indications for polysomnography and related procedures. Sleep. 1997;20:506–22. [PubMed: 9302725]
    43.
    Sadeh A, Hauri PJ, Kripke DF. et al. The role of actigraphy in the evaluation of sleep disorders. Sleep. 1995;18:55–7. [PubMed: 7618029]
    44.
    Drummond SA, Smith MT, Orff HJ. et al. Functional imaging of the sleeping brain: review of findings and implications for the study of insomnia. Sleep Med Rev. 2004;8:227–42. [PubMed: 15144964]
    45.
    Bonnett MH, Arand D. 24 hour metabolic rate in insomniacs and matched normal sleepers. Sleep. 1995;18(7):581–8. [PubMed: 8552929]
    46.
    Vgontzas AN, Tsigos C, Bixler EO. et al. Chronic insomnia and activity of the stress system: a preliminary study. J Psychosom Res. 1998;45(1 Spec No):21–31. [PubMed: 9720852]
    47.
    Bastien CH, Morin CM. Familial incidence of insomnia. J Sleep Res. 2000;9(1):49–54. [PubMed: 10733689]
    48.
    Yves D, Morin C, Cervena K, et al. Family studies in insomnia (abstract). Sleep 2003; 26(suppl):A:304, A0764 2003; 26(Suppl A):304.
    49.
    Krystal A, Roth T. Definitions, measurements, and management in insomnia. J Clin Psychiatry. 2004;65(Suppl 8):5–7. [PubMed: 15153061]
    50.
    Foley DJ, Monjan AA, Izmirlian G. et al. Incidence and remission of insomnia among elderly adults in a biracial cohort. Sleep. 1999;22 Suppl 2:S373–8. [PubMed: 10394610]
    51.
    Millar A, Espie CA, Scott J. The sleep of remitted bipolar outpatients: A controlled naturalistic study using actigraphy. J Affect Disord. 2004;80(23):145–53. [PubMed: 15207927]
    52.
    Hajak G. SINE Study Group; Study of Insomnia in Europe. Epidemiology of severe insomnia and its consequences in Germany. Eur Arch Psychiatry Clin Neurosci. 2001;251(2):49–56. [PubMed: 11407438]
    53.
    Hohagen F, Kappler C, Schramm E. et al. Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening--temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep. 1994;17(6):551–4. [PubMed: 7809569]
    54.
    Hetta J, Broman JE, Mallon L. Evaluation of severe insomnia in the general population--implications for the management of insomnia: insomnia, quality of life and healthcare consumption in Sweden. J Psychopharmacol. 1999;13(4 Suppl 1):S35–6. [PubMed: 10667458]
    55.
    Savard J, Simard S, Blanchet J. et al. Prevalence, clinical characteristics, and risk factors for insomnia in the context of breast cancer. Sleep. 2001;24(5):583–90. [PubMed: 11480655]
    56.
    Millar A, Espie CA, Scott J. The sleep of remitted bipolar outpatients: A controlled naturalistic study using actigraphy. J Affect Disord. 2004;80(23):145–53. [PubMed: 15207927]
    57.
    Kageyama T, Nishikido N, Kobayashi T. et al. Cross-sectional survey on risk factors for insomnia in Japanese female hospital nurses working rapidly rotating shift systems. J Hum Ergol. 2001;30(12):149–54. [PubMed: 14564874]
    58.
    Bixler EO, Vgontzas AN, Lin HM. et al. Insomnia in Central Pennsylvania. J Psychosom Res. 2002;53(1):589–92. [PubMed: 12127176]
    59.
    Riedel BW, Durrence H, Lichstein KL. et al. The Relation Between Smoking and Sleep: The Influence of Smoking Level, Health, and Psychological Variables. Behav Sleep Med. 2004;2(1):63–78. [PubMed: 15600225]
    60.
    Lopes Rocha F, Guerra HL, Lima-Costa MFF. Prevalence of insomnia and associated socio-demographic factors in a Brazilian community: The Bambui study. Sleep Med. 2002;3(2):121–6. [PubMed: 14592230]
    61.
    Martikainen K, Partinen M, Hasan J. et al. The impact of somatic health problems on insomnia in middle age. Sleep Med. 2003;4(3):201–6. [PubMed: 14592322]
    62.
    Terzano MG, Parrino L, Cirignotta F. et al. Studio Morfeo: insomnia in primary care, a survey conducted on the Italian population. Sleep Med. 2004;5(1):67–75. [PubMed: 14725829]
    63.
    Zammit GK, Weiner J, Damato N. et al. Quality of life in people with insomnia. Sleep. 1999;22(Suppl 2):S379–85. [PubMed: 10394611]
    64.
    Shochat T, Umphress J, Israel AG. et al. Insomnia in primary care patients. Sleep. 1999;22(Suppl 2):S359–65. [PubMed: 10394608]
    65.
    Perlis ML, Smith MT, Orff HJ. et al. The mesograde amnesia of sleep may be attenuated in subjects with primary insomnia. Physiol Behav. 2001;74(12):71–6. [PubMed: 11564454]
    66.
    Moher D, Pham B, Lawson M. et al. The inclusion of reports of randomized trials published in languages other than English in systematic reviews National Health Service (NHS) Research and Development Program (Health Technology Assessment Report). Health Technol Assess. 2003;7:1–90. [PubMed: 14670218]
    67.
    Benca RM, Ancoli-Israel S, Moldofsky H. Special considerations in insomnia diagnosis and management: depressed, elderly, and chronic pain populations. J Clin Psychiatry. 2004;65(Suppl 8):26–35. [PubMed: 15153065]
    68.
    Miller EH. Women and insomnia. Clin Cornerstone. 2004;6(Suppl 1B):S8–18. [PubMed: 15457811]
    69.
    Panneman MJ, Goettsch WG, Kramarz P. et al. The costs of benzodiazepine-associated hospital-treated fall Injuries in the EU: a Pharmo study. Drugs Aging. 2003;20(11):833–9. [PubMed: 12964889]
    70.
    Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet. 2004;43(4):227–38. [PubMed: 15005637]
    71.
    Roehrs T, Roth T. Hypnotics: an update. Curr Neurol Neurosci Rep. 2003;3(2):181–4. [PubMed: 12583849]
    72.
    Nowell PD, Mazumdar S, Buysse DJ. et al. Benzodiazepines and zolpidem for chronic insomnia: meta-analysis of treatment efficacy. J Am Med Assoc. 1997;278:2170–7. [PubMed: 9417012]
    73.
    Holbrook AM, Crowther R, Lotter A. et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. Can Med Assoc J. 2000;162(2):225–33. [PMC free article: PMC1232276] [PubMed: 10674059]
    74.
    Smith MT, Perlis ML, Park A. et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry. 2002;159:5–11. [PubMed: 11772681]
    75.
    Buscemi N, Vandermeer B, Pandya R, et al. Melatonin for treatment of sleep disorders. Evid Rep Technol Assess 2004;(108):1–7. [PMC free article: PMC4781368] [PubMed: 15635761]
    76.
    Montgomery P, Dennis J. Cognitive behavioural interventions for sleep problems in adults aged 60+ [review]. Cochrane Database Syst Rev 2003; 1(Art. No.: CD003161. DOI: 10.1002/14651858. CD003161). [PubMed: 12076472]
    77.
    Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: A meta-analysis of treatment efficacy. Am J Psychiatry. 1994;151(8):1172–80. [PubMed: 8037252]
    78.
    Murtagh DRR, Greenwood KM. Identifying effective psychological treatments for insomnia: a meta-analysis. J Consult Clin Psychol. 1995;63(1):79–89. [PubMed: 7896994]

    Included Studies

    1.
    Aden GC, Thatcher C. Quazepam in the short-term treatment of insomnia in outpatients. J Clin Psychiatry. 1983;44(12):454–6. [PubMed: 6361006]
    2.
    Allain H, Arbus L, Schuck S. Efficacy and safety of zolpidem administered as needed in primary insomnia: results of a double-blind, placebo-controlled study. Clin Drug Invest. 2001;21(6):391–400.
    3.
    Allain H, Le Coz F, Borderies P. et al. Use of zolpidem 10 mg as a benzodiazepine substitute in 84 patients with insomnia. Hum Psychopharmacol. 1998;13(8):551–9.
    4.
    Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. Sleep. 1999;22(Suppl 2):S347–53. [PubMed: 10394606]
    5.
    Ascher LM, Turner RM. Paradoxical intention and insomnia: An experimental investigation. Behav Res Ther. 1979;17(4):408–11. [PubMed: 486046]
    6.
    Asnis GM, Chakraburtty A, DuBoff EA. et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry. 1999;60(10):668–76. [PubMed: 10549683]
    7.
    Bastien CH, Fortier-Brochu E, Rioux I. et al. Cognitive performance and sleep quality in the elderly suffering from chronic insomnia. Relationship between objective and subjective measures.[erratum appears in J Psychosom Res. 2003 Nov;55(5):475] J Psychosom Res. 2003;54(1):39–49. [PubMed: 12505554]
    8.
    Beary MD, Lacey JH, Crutchfield MB. et al. Psycho-social stress, insomnia and temazepam: a sleep laboratory evaluation in a “general practice” sample. Psychopharmacol. 1984;83(1):17–9. [PubMed: 6146153]
    9.
    Bixler EO, Kales A, Soldatos CR. et al. Prevalence of sleep disorders in the Los Angeles metropolitan area. Am J Psychiatry. 1979;136(10):1257–62. [PubMed: 314756]
    10.
    Bixler EO, Vgontzas AN, Lin HM. et al. Insomnia in Central Pennsylvania. J Psychosom Res. 2002;53(1):589–92. [PubMed: 12127176]
    11.
    Bliwise NG. Factors related to sleep quality in healthy elderly women. Psychol Aging. 1992;7(1):83–8. [PubMed: 1558709]
    12.
    Bonnet MH, Arand DL. 24-Hour metabolic rate in insomniacs and matched normal sleepers. Sleep. 1995;18(7):581–8. [PubMed: 8552929]
    13.
    Botter PA. Comparative double blind study of loprazolam, 1 mg and 2 mg, versus placebo in anxiety induced insomnia. Curr Med Res Opin. 1983;8(9):626–30. [PubMed: 6141896]
    14.
    Bowen AJ. Comparative efficacy of triazolam, flurazepam and placebo in out-patient insomniacs. J Int Med Res. 1978;6(4):337–42. [PubMed: 28989]
    15.
    Braga-Neto P, Da Silva FP, Monte FS. et al. Snoring and excessive daytime sleepiness in Parkinson's Disease. J Neurol Sci. 2004;217(1):41–5. [PubMed: 14675608]
    16.
    Broman JE, Lundh LG, Aleman K. et al. Subjective and objective performance in patients with persistent insomnia. Scand J Behav Ther. 1992;21(3):115–26.
    17.
    Broman JE, Lundh LG, Hetta J. Insufficient sleep in the general population. Neurophysiol Clin. 1996;26(1):30–9. [PubMed: 8657096]
    18.
    Brown CC, Horrom NJ, Wagman AM. Effects of L-tryptophan on sleep onset insomniacs. Waking Sleeping. 1979;3(2):101–8. [PubMed: 227180]
    19.
    Campbell RD, Grace MGA, Bourgouin J. et al. Efficacy and safety of zopiclone in the treatment of insomnia. Curr Ther Res. 1987;42(4):665–70.
    20.
    Carr-Kaffashan L, Woolfolk RL. Active and placebo effects in treatment of moderate and severe insomnia. J Consult Clin Psychol. 1979;47(6):1072–80. [PubMed: 41856]
    21.
    Chambers MJ, Kim JY. The role of state-trait anxiety in insomnia and daytime restedness. Behav Med. 1993;19(1):42–6. [PubMed: 8219529]
    22.
    Chaudoir PJ, Jarvie NC, Wilcox GJ. The acceptability of a non-benzodiazepine hypnotic (Zopiclone) in general practice. J Int Med Res. 1983;11(6):333–7. [PubMed: 6360747]
    23.
    Choliz M. A breathing-retraining procedure in treatment of sleep-onset insomnia: theoretical basis and experimental findings. Percept Mot Skills. 1995;80(2):507–13. [PubMed: 7675582]
    24.
    Cohn JB, Wilcox CS, Bremner J. et al. Hypnotic efficacy of estazolam compared with flurazepam in outpatients with insomnia. J Clin Pharmacol. 1991;31:747–50. [PubMed: 1880233]
    25.
    Cohn JB. Double-blind crossover comparison of triazolam and lorazepam in the posthypnotic state. J Clin Psychiatry. 1984;45(3):104–7. [PubMed: 6142034]
    26.
    Cohn JB. Triazolam treatment of insomnia in depressed patients taking tricyclics. J Clin Psychiatry. 1983;44(11):401–6. [PubMed: 6139364]
    27.
    Coursey RD, Buchsbaum M, Frankel BL. Personality measures and evoked responses in chronic insomniacs. J Abnorm Psychol. 1975;84(3):239–49. [PubMed: 1133252]
    28.
    Coxeter PD, Schluter PJ, Eastwood HL. et al. Valerian does not appear to reduce symptoms for patients with chronic insomnia in general practice using a series of randomised N-of-I trials. Complement Ther Med. 2003;11(4):215–22. [PubMed: 15022653]
    29.
    Crenshaw MC, Edinger JD. Slow-wave sleep and waking cognitive performance among older adults with and without insomnia complaints. Physiol Behav. 1999;66(3):485–92. [PubMed: 10357438]
    30.
    Davies R, Lacks P, Storandt M. et al. Countercontrol treatment of sleep-maintenance insomnia in relation to age. Psychol Aging. 1986;1(3):233–8. [PubMed: 3267403]
    31.
    Dawson D, Rogers NL, van den Heuvel CJ. et al. Effect of sustained nocturnal transbuccal melatonin administration on sleep and temperature in elderly insomniacs. J Biol Rhythms. 1998;13(6):532–8. [PubMed: 9850013]
    32.
    Declerck A, Smits M. Zolpidem, a valuable alternative to benzodiazepine hypnotics for chronic insomnia? J Int Med Res. 1999;27(6):253–63. [PubMed: 10726234]
    33.
    Dominguez RA, Goldstein BJ, Jacobson AF. et al. Brotizolam in the treatment of insomnia. Psychopharmacol Bull. 1985;21(1):97–100. [PubMed: 3885295]
    34.
    Dominguez RA, Goldstein BJ, Jacobson AF. et al. Comparative efficacy of estazolam, flurazepam, and placebo in outpatients with insomnia. J Clin Psychiatry. 1986;47(7):362–5. [PubMed: 2873132]
    35.
    Donath F, Quispe S, Diefenbach K. et al. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry. 2000;33(2):47–53. [PubMed: 10761819]
    36.
    Dorsey CM, Bootzin RR. Subjective and psychophysiologic insomnia: An exmaination of sleep tendency and personality. Biol Psychiatry. 1997;41(2):209–16. [PubMed: 9018392]
    37.
    Drake CL, Roehrs TA, Mangano RM. et al. Dose-response effects of zaleplon as compared with triazolam (0.25 mg) and placebo in chronic primary insomnia. Hum Psychopharmacol. 2000;15(8):595–604. [PubMed: 12404612]
    38.
    Dujardin K, Guieu JD, Leconte-Lambert C. et al. Comparison of the effects of zolpidem and flunitrazepam on sleep structure and daytime cognitive functions. A study of untreated unsomniacs. Pharmacopsychiatry. 1998;31(1):14–8. [PubMed: 9524979]
    39.
    Edinger JD, Glenn DM, Bastian LA. et al. Slow-wave sleep and waking cognitive performance II: Findings among middle-aged adults with and without insomnia complaints. Physiol Behav. 2000;70(12):127–34. [PubMed: 10978487]
    40.
    Edinger JD, Sampson WS. A Primary Care “Friendly” Cognitive Behavioral Insomnia Therapy. Sleep. 2003;26(2):177–182. [PubMed: 12683477]
    41.
    Edinger JD, Wohlgemuth W, Radtke R. et al. Cognitive behavioral therapy for treatment of chronic primary insomnia: A randomized controlled trial. [References] J Am Med Assoc. 2001;285(14):1856–64. [PubMed: 11308399]
    42.
    Edinger JD, Fins AI, Glenn DM. et al. Insomnia and the eye of the beholder: are there clinical markers of objective sleep disturbances among adults with and without insomnia complaints? J Consult Clin Psychol. 2000;68(4):586–93. [PubMed: 10965634]
    43.
    Elie R, Frenay M, Le Morvan P. et al. Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs. Int Clin Psychopharmacol. 1990;5(Suppl 2):39–46. [PubMed: 2201729]
    44.
    Elie R, Ruther E, Farr I. et al. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. J Clin Psychiatry. 1999;60(8):536–44. [PubMed: 10485636]
    45.
    Ellis CM, Lemmens G, Parkes JD. Melatonin and insomnia. J Sleep Res. 1996;5(1):61–5. [PubMed: 8795804]
    46.
    Espie CA, Lindsay WR, Brooks DN. et al. A controlled comparative investigation of psychological treatments for chronic sleep-onset insomnia. Behav Res Ther. 1989;27(1):79–88. [PubMed: 2914008]
    47.
    Farag NH, Mills PJ. A randomised-controlled trial of the effects of a traditional herbal supplement on sleep onset insomnia. Complement Thera Med. 2003;11(4):223–5. [PubMed: 15022654]
    48.
    Ferguson JM, Bielski RJ, Houston J. et al. Comparison of estazolam and placebo in the outpatient treatment of insomnia associated with major depression. Curr Ther Res. 1991;49(5):898–907.
    49.
    Fichtenberg NL, Zafonte RD, Putnam S. et al. Insomnia in a post-acute brain injury sample. Brain Inj. 2002;16(3):197–206. [PubMed: 11874613]
    50.
    Fillingim JM. Double blind evaluation of temazepam, flurazepam, and placebo in geriatric insomniacs. Clin Ther. 1982;4(5):369–80. [PubMed: 6121625]
    51.
    Fleming J, Moldofsky H, Walsh JK. et al. Comparison of the residual effects and efficacy of short term zolpidem, flurazepam and placebo in patients with chronic insomnia. Clin Drug Invest. 1995;9:303–13.
    52.
    Fry J, Scharf M, Mangano R. et al. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group. Int Clin Psychopharmacol. 2000;15(3):141–52. [PubMed: 10870872]
    53.
    Garfinkel D, Laudon M, Nof D. et al. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet. 1995;346:541–4. [PubMed: 7658780]
    54.
    Garfinkel D, Laudon M, Zisapel N. Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomniacs. Arch -Gerontol Geriatr. 1997;24(2):223–31. [PubMed: 15374128]
    55.
    Gelinas B, Thorsteinson L, Lapierre YD. et al. Zopiclone in the treatment of insomniacs of family practice. Psychiatr J Univ Ottawa. 1985;10(3):165–8. [PubMed: 3903810]
    56.
    Goethe JW, Kader G. Short-term clinical study of quazepam 15 mg in outpatient insomniacs. Curr Ther Res. 1982;32:150–6.
    57.
    Goldenberg F, Hindmarch I, Joyce CRB. et al. Zopiclone, sleep and health-related quality of life. Hum Psychopharmacol. 1994;9(4):245–51.
    58.
    Haffmans PMJ, Vos MS. The effects of trazodone on sleep disturbances induced by brofaromine. Eur Psychiatry. 1999;14(3):167–71. [PubMed: 10572343]
    59.
    Haimov I, Lavie P, Laudon M. et al. Melatonin replacement therapy of elderly insomniacs. Sleep. 1995;18(7):598–603. [PubMed: 8552931]
    60.
    Hajak G, Clarenbach P, Fischer W. et al. Zopiclone improves sleep quality and daytime well-being in insomniac patients: comparison with triazolam, flunitrazepam and placebo. Int Clin Psychopharmacol. 1994;9(5):251–61. [PubMed: 7868847]
    61.
    Hajak G, Rodenbeck A, Adler L. et al. Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. Pharmacopsychiatry. 1996;29(5):187–92. [PubMed: 8895944]
    62.
    Hajak G, Rodenbeck A, Voderholzer U, et al. Doxepin in the treatment of primary insomnia - a placebo-controlled, double-blind, polysomnographic study [abstract]. In: J Eur Coll Neuropsychopharmacol. Proceedings of the 13th ECNP Congress; 2000 Sep 9–13; Munich, Germany. Suppl 3, S248. [PubMed: 11465523]
    63.
    Hajak G. SINE Study Group; Study of Insomnia in Europe. Epidemiology of severe insomnia and its consequences in Germany. Eur Arch Psychiatry Clin Neurosci. 2001;251(2):49–56. [PubMed: 11407438]
    64.
    Han SY, Yoon JW, Jo SK. et al. Insomnia in diabetic hemodialysis patients: Prevalence and risk factors by a multicenter study. Nephron. 2002;92(1):127–32. [PubMed: 12187095]
    65.
    Hartmann E, Lindsley JG, Spinweber C. Chronic insomnia effects of tryptophan, flurazepam, seco bartibal and placebo. Psychopharmacol. 1983;80(2):138–42. [PubMed: 6410442]
    66.
    Harvey AG, Greenall E. Catastrophic worry in primary insomnia. J Behav Ther Exp Psychiatry. 2003;34(1):11–23. [PubMed: 12763390]
    67.
    Harvey AG. The attempted suppression of presleep cognitive activity in insomnia. Cognit Ther Res. 2003;27(6):593–602.
    68.
    Hauri PJ. Cognitive deficits in insomnia patients. Acta Neurol Belg. 1997;97(2):113–7. [PubMed: 9246379]
    69.
    Haynes SN, Sides H, Lockwood G. Relaxation instructions and frontalis electromyographic feedback intervention with sleep-onset insomnia. Behav Ther. 1977;8(4):644–52.
    70.
    Haynes SN, Woodward S, Moran R. et al. Relaxation treatment of insomnia. Behav Ther. 1974;5(4):555–8.
    71.
    Healey ES, Kales A, Monroe LJ. et al. Onset of insomnia: role of life-stress events. Psychosom Med. 1981;43(5):439–51. [PubMed: 7313035]
    72.
    Hedner J, Yaeche R, Emilien G. et al. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group. Int J Geriatr Psychiatry. 2000;15(8):704–12. [PubMed: 10960882]
    73.
    Heidrich H, Ott H, Beach RC. Lormetazepam A benzodiazepine derivative without hangover effect. A double-blind study with chronic insomniacs in a general practice setting. Int J Clin Pharmacol Ther Toxicol. 1981;19(1):11–17. [PubMed: 6110634]
    74.
    Hernandez LR, Del Rosal PL, Ponce MC. Short-term study of quazepam 15 milligrams in the treatment of insomnia. J Inte Med Res. 1983;11(3):162–6. [PubMed: 6347748]
    75.
    Herrmann WM, Kubicki ST, Boden S. et al. Pilot controlled double-blind study of the hypnotic effects of zolpidem in patients with chronic ‘learned’ insomnia: Psychometric and polysomnographic evaluation. J Int Med Res. 1993;21(6):306–22. [PubMed: 8143886]
    76.
    Hetta J, Broman JE, Mallon L. Evaluation of severe insomnia in the general population--implications for the management of insomnia: insomnia, quality of life and healthcare consumption in Sweden. J Psychopharmacol. 1999;13(4 Suppl 1):S35–6. [PubMed: 10667458]
    77.
    Hidalgo MP, Caumo W. Sleep distrubances associated with minor psychiatric disorders in medical students. Neurol Sci. 2002;23(1):35–9. [PubMed: 12111619]
    78.
    Hohagen F, Kappler C, Schramm E. et al. Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening--temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep. 1994;17(6):551–4. [PubMed: 7809569]
    79.
    Hohagen F, Kappler C, Schramm E. et al. Prevalence of insomnia in elderly general practice attenders and the current treatment modalities. Acta Psychiatr Scand. 1994;90(2):102–8. [PubMed: 7976454]
    80.
    Hohagen F, Rink K, Kaeppler C. et al. Prevalence and treatment of insomnia in general practice: A longitudinal study. Eur Arch Psychiatry Clin Neurosci. 1993;242(6):329–36. [PubMed: 8323982]
    81.
    Hughes RC, Hughes HH. Insomnia: Effects of EMG biofeedback, relaxation training, and stimulus control. Behav Eng. 1978;5(2):67–72.
    82.
    Ishigooka J, Suzuki M, Isawa S. et al. Epidemiological study on sleep habits and insomnia of new outpatients visiting general hospitals in Japan. Psychiatry Clin Neurosci. 1999;53(4):515–22. [PubMed: 10498235]
    83.
    Jacobson AF, Dominguez RA, Goldstein BJ. et al. Efficacy of brotizolam in geriatric patients with insomnia. Curr Ther Res. 1986;39:528–36.
    84.
    James S, Sack D, Rosenthal N. et al. Melatonin administration in insomnia. Neuropsychopharmacol. 1990;3(1):19–24. [PubMed: 2306332]
    85.
    Kageyama T, Kabuto M, Nitta H. et al. A population study on risk factors for insomnia among adult Japanese women: a possible effect of road traffic volume. Sleep. 1997;20(11):963–71. [PubMed: 9456461]
    86.
    Kageyama T, Nishikido N, Kobayashi T. et al. Cross-sectional survey on risk factors for insomnia in Japanese female hospital nurses working rapidly rotating shift systems. J Hum Ergol. 2001;30(12):149–54. [PubMed: 14564874]
    87.
    Kales A, Caldwell AB, Soldatos CR. et al. Biopsychobehavioral correlates of insomnia. II. Pattern specificity and consistency with the Minnesota Multiphasic Personality Inventory. Psychosom Med. 1983;45(4):341–56. [PubMed: 6622623]
    88.
    Kales A, Bixler EO, Soldatos CR. et al. Biopsychobehavioral correlates of insomnia: I. Role of sleep apnea and nocturnal myoclonus. Psychosomat J Consult Liais Psychiatry. 1982;23(6):589–600. [PubMed: 7122793]
    89.
    Kales JD, Kales A, Bixler EO. et al. Biopsychobehavioral correlates of insomnia, V: Clinical characteristics and behavioral correlates. Am J Psychiatry. 1984;141(11):1371–6. [PubMed: 6496780]
    90.
    Kappler C, Hohagen F. Psychosocial aspects of insomnia: Results of a study in general practice. Eur Arch Psychiatry Clin Neurosci. 2003;253(1):49–52. [PubMed: 12664315]
    91.
    Kawada T, Yosiaki S, Yasuo K. et al. Population study on the prevalence of insomnia and insomnia-related factors among Japanese women. Sleep Med. 2003;4(6):563–7. [PubMed: 14607351]
    92.
    Krystal AD, Walsh JK, Laska E. et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic Iisomnia. Sleep. 2003;26(7):793–9. [PubMed: 14655910]
    93.
    Lacks P, Bertelson AD, Sugerman J. et al. Treatment of sleep maintenance insomnia with stimulus control techniques. Behav Res Ther. 1983;21(3):291–6. [PubMed: 6615394]
    94.
    Lacks P, Bertelson AD, Gans L. et al. The effectiveness of three behavioral treatments for different degrees of sleep onset insomnia. Behav Ther. 1983;14(5):593–605.
    95.
    Lahmeyer H, Wilcox CS, Kann J. et al. Subjective efficacy of zolpidem in outpatients with chronic insomnia: double blind comparison with placebo. Clin Drug Invest. 1997;13:134–44.
    96.
    Lamphere JK, Roehrs TA, Zorick FJ. et al. The dose effects of zopiclone. Hum Psychopharmacol. 1989;4(1):41–6. [PubMed: 2651493]
    97.
    Leger D, Guilleminault C, Dreyfus JP. et al. Prevalence of insomnia in a survey of 12,778 adults in France. J Sleep Res. 2000;9(1):35–42. [PubMed: 10733687]
    98.
    Leppavuori A, Pohjasvaara T, Vataja R. et al. Insomnia in ischemic stroke patients. Cerebrovasc Dis. 2002;14(2):90–7. [PubMed: 12187012]
    99.
    Leppik IE, Roth-Schechter GB, Gray GW. et al. Double blind, placebo controlled comparison of zolpidem, triazolam, and temazepam in elderly patients with insomnia. Drug Dev Res. 1997;40:230–8.
    100.
    Levitt H, Wood A, Moul DE. et al. A pilot study of subjective daytime alertness and mood in primary insomnia participants using ecological momentary assessment. Behav Sleep Med. 2004;2(2):113–31. [PubMed: 15600228]
    101.
    Lichstein KL, Durrence HH, Bayen UJ. et al. Primary versus secondary insomnia in older adults: subjective sleep and daytime functioning. Psychol Aging. 2001;16(2):264–71. [PubMed: 11405314]
    102.
    Lichstein KL, Riedel BW, Wilson NM. et al. Relaxation and sleep compression for late-life insomnia: a placebo-controlled trial. J Consult Clin Psychol. 2001;69(2):227–39. [PubMed: 11393600]
    103.
    Linzmayer L, Arnold O, Saletu-Zyhlarz GM. et al. Daytime noopsychic and thymopsychic dysfunctions in nonorganic insomnia related to different mental disorders. Somnologie. 2002;6(4):141–8.
    104.
    Lopes Rocha F, Guerra HL, Lima-Costa MFF. Prevalence of insomnia and associated socio-demographic factors in a Brazilian community: The Bambui study. Sleep Med. 2002;3(2):121–6. [PubMed: 14592230]
    105.
    Lundh L-G, Froeding A, Gyllenhammar L. et al. Cognitive bias and memory performance in patients with persistent insomnia. Scand J Behav Ther. 1997;26(1):27–35.
    106.
    Mamelak M, Buck L, Csima A. et al. Effects of flurazepam and zopiclone on the performance of chronic insomniac patients: a study of ethanol-drug interaction. Sleep. 1987;10(Suppl 1):79–87. [PubMed: 3438646]
    107.
    Mamelak M, Csima A, Buck L. et al. A comparative study on the effects of brotizolam and flurazepam on sleep and performance in the elderly. J Clin Psychopharmacol. 1989;9(4):260–7. [PubMed: 2671059]
    108.
    Martikainen K, Partinen M, Hasan J. et al. The impact of somatic health problems on insomnia in middle age. Sleep Med. 2003;4(3):201–6. [PubMed: 14592322]
    109.
    McAlpine CJ, Ankier SI, Elliott CS. A multicentre hospital study to compare the hypnotic efficacy of loprazolam and nitrazepam. J Int Med Res. 1984;12(4):229–37. [PubMed: 6147285]
    110.
    Melo de Paula AJ. Comparative study of lormetazepam and flurazepam in the treatment of insomnia. Clin Ther. 1984;6(4):500–8. [PubMed: 6380724]
    111.
    Mendels J, Stern S. Evaluation of the short-term treatment of insomnia in out patients with 15 milligrams of quazepam. J Int Med Res. 1983;11(3):155–61. [PubMed: 6347747]
    112.
    Mendelson WB, Garnett D, Gillin JC. et al. The experience of insomnia and daytime and nighttime functioning. Psychiatry Res. 1984;12(3):235–50. [PubMed: 6593755]
    113.
    Milby JB, Williams V, Hall JN. et al. Effectiveness of combined triazolam-behavioral therapy for primary insomnia. Am J Psychiatry. 1993;150:1259–60. [PubMed: 8328575]
    114.
    Millar A, Espie CA, Scott J. The sleep of remitted bipolar outpatients: A controlled naturalistic study using actigraphy. J Affect Disord. 2004;80(23):145–53. [PubMed: 15207927]
    115.
    Minnekeer R, Marchal J, Van de Velde L. et al. A double-blind study comparing the efficacy and safety of quazepam with flunitrazepam and placebo in patients with chronic insomnia. Acta Ther. 1988;14(2):159–70.
    116.
    Mitchell KR. Behavioral treatment of presleep tension and intrusive cognitions in patients with severe predormital insomnia. J Behav Med. 1979;2(1):57–69. [PubMed: 555480]
    117.
    Mitler MM, Seidel WF, van den Hoed J. et al. Comparative hypnotic effects of flurazepam, triazolam, and placebo: a long-term simultaneous nighttime and daytime study. J Clin Psychopharmacol. 1984;4(1):2–13. [PubMed: 6141188]
    118.
    Monchesky TC, Billings BJ, Phillips R. Zopiclone: a new nonbenzodiazepine hypnotic used in general practice. Clin Ther. 1986;8(3):283–91. [PubMed: 3521857]
    119.
    Montes LG, Uribe MP, Sotres JC. et al. Treatment of primary insomnia with melatonin: A double-blind, placebo-controlled, crossover study. J Psychiatry Neurosci. 2003;28(3):191–6. [PMC free article: PMC161743] [PubMed: 12790159]
    120.
    Monti JM, Monti D, Estevez F, et al. Sleep in patients with chronic primary insomnia during long-term zolpidem administration and after its withdrawal. Int Clin Psychopharmacol 1996; 114(255–63). [PubMed: 9031992]
    121.
    Monti JM, Alvarino F, Monti D. Conventional and power spectrum analysis of the effects of zolpidem on sleep EEG in patients with chronic primary insomnia. Sleep. 2000;23(8):1075–84. [PubMed: 11145322]
    122.
    Morin CM, Colecchi C, Stone J. et al. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial.[comment] J Am Med Assoc. 1999;281(11):991–9. [PubMed: 10086433]
    123.
    Nair NP, Schwartz G, Dimitri R. et al. A dose-range finding study of zopiclone in insomniac patients. Int Clin Psychopharmacol. 1990;5(Suppl 2):1–10. [PubMed: 2201721]
    124.
    Negri L. Evaluation of the efficacy of pivagabine on insomnia associated with mood disorders. Arzneimittel Forschung. 1997;47(11 Suppl a):1322–5. [PubMed: 9450157]
    125.
    Nicassio P, Bootzin R. A comparison of progressive relaxation and autogenic training as treatments for insomnia. J Abnorm Psychol. 1974;83(3):253–60. [PubMed: 4844912]
    126.
    Niemcewicz S, Szelenberger W. Psychophysiological correlates of primary insomnia. Arch Hellenic Med. 2001;18(1):64–8. [PubMed: 11760459]
    127.
    Ohayon MM. Prevalence of DSM-IV diagnostic criteria of insomnia: distinguishing insomnia related to mental disorders from sleep disorders. J Psychiatr Res. 1997;31(3):333–46. [PubMed: 9306291]
    128.
    Ohayon MM, Hong SC. Prevalence of insomnia and associated factors in South Korea. J Psychosom Res. 2002;53(1):593–600. [PubMed: 12127177]
    129.
    Ohayon MM, Partinen M. Insomnia and global sleep dissatisfaction in Finland. J Sleep Res. 2002;11(4):339–36. [PubMed: 12464102]
    130.
    Ohayon MM, Roberts RE. Comparability of sleep disorders diagnoses using DSM-IV and ICSD classifications with adolescents. Sleep. 2001;24(8):920–5. [PubMed: 11766162]
    131.
    Ohayon MM, Roberts RE, Zulley J. et al. Prevalence and patterns of problematic sleep among older adolescents. J Am Acad Child Adolesc Psychiatry. 2000;39(12):1549–56. [PubMed: 11128333]
    132.
    Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatric Res. 2003;37(1):9–15. [PubMed: 12482465]
    133.
    Ohayon MM, Roth T. What are the contributing factors for insomnia in the general population? J Psychosom Res. 2001;51(6):745–55. [PubMed: 11750297]
    134.
    Ohayon MM, Smirne S. Prevalence and consequences of insomnia disorders in the general population of Italy. Sleep Med. 2002;3(2):115–20. [PubMed: 14592229]
    135.
    Ohayon MM, Zulley J, Guilleminault C. et al. How age and daytime activities are related to insomnia in the general population: consequences for older people.[see comment] J Am Geriatr Soc. 2001;49(4):360–6. [PubMed: 11347777]
    136.
    Ohayon MM, Caulet M, Arbus L. et al. Are prescribed medications effective in the treatment of insomnia complaints? [References] J Psychosom Res. 1999;47(4):359–68. [PubMed: 10616230]
    137.
    Pallesen S, Nordhus IH, Kvale G. et al. Psychological characteristics of elderly insomniacs. Scand J Psychol. 2002;43(5):425–32. [PubMed: 12500782]
    138.
    Pasche B, Erman M, Hayduk R. et al. Effects of low energy emission therapy in chronic psychophysiological insomnia. Sleep. 1996;19(4):327–36. [PubMed: 8776791]
    139.
    Pavlova M, Berg O, Gleason R. et al. Self-reported hyperarousal traits among insomnia patients. J Psychosom Res. 2001;51(2):435–41. [PubMed: 11516766]
    140.
    Perlis ML, Smith MT, Orff H. et al. The effects of modafinil and cognitive behavior therapy on sleep continuity in patients with primary insomnia. Sleep. 2004;27(4):715–25. [PubMed: 15283007]
    141.
    Perlis ML, Smith MT, Orff HJ. et al. The mesograde amnesia of sleep may be attenuated in subjects with primary insomnia. Physiol Behav. 2001;74(12):71–6. [PubMed: 11564454]
    142.
    Poyares DR, Guilleminault C, Ohayon MM. et al. Can valerian improve the sleep of insomniacs after benzodiazepine withdrawal? Prog NeuroPsychopharmacol Biol Psychiatry. 2002;26(3):539–45. [PubMed: 11999905]
    143.
    Reeves RL. Comparison of triazolam, flurazepam and placebo as hypnotics in geriatric patients with insomnia. J Clin Pharmacol. 1977;17:319–23. [PubMed: 16041]
    144.
    Rickels K, Morris RJ, Mauriello R. et al. Brotizolam, a triazolothienodiazepine, in insomnia. Clin Pharmacol Ther. 1986;40:293–9. [PubMed: 3527513]
    145.
    Riedel BW, Durrence H, Lichstein KL. et al. The Relation Between Smoking and Sleep: The Influence of Smoking Level, Health, and Psychological Variables. Behav Sleep Med. 2004;2(1):63–78. [PubMed: 15600225]
    146.
    Riemann D, Voderholzer U, Cohrs S. et al. Trimipramine in Primary Insomnia: Results of a Polysomnographic Double-Blind Controlled Study. Pharmacopsychiatry. 2002;35(5):165–74. [PubMed: 12237787]
    147.
    Robbins L. Anxiety, depression, and insomnia in migraine: A retrospective review of 494 patients. Headache Q. 1995;6(4):303–5. [PubMed: 8014037]
    148.
    Rocha FL, Uchoa E, Guerra HL. et al. Prevalence of sleep complaints and associated factors in community-dwelling order people in Brazil: The Bambui health and ageing study (BHAS). Sleep Med. 2002;3(3):231–8. [PubMed: 14592212]
    149.
    Rodenbeck A, Cohrs S, Jordan W. et al. The Sleep-Improving Effects of Doxepin Are Paralleled by a Normalized Plasma Cortisol Secretion in Primary Insomnia - a Placebo-Controlled, Double-Blind, Randomized, Cross-Over Study Followed by an Open Treatment Over 3 Weeks. Psychopharmacol. 2003;170(4):423–8. [PubMed: 13680082]
    150.
    Roehrs T, Papineau K, Rosenthal L. et al. Ethanol as a hypnotic in insomniacs: self administration and effects on sleep and mood. Neuropsychopharmacol. 1999;20(3):279–86. [PubMed: 10063488]
    151.
    Roehrs T, Zorick F, Koshorek GL. et al. Effects of acute administration of brotizolam in subjects with disturbed sleep. Br J Clin Pharmacol. 1983;16(Suppl 2):S371–6. [PMC free article: PMC1428220] [PubMed: 6661383]
    152.
    Roth T, Tietz EI, Kramer M. et al. The effect of a single dose of quazepam (Sch-16134) on the sleep of chronic insomniacs. J Int Med Res. 1979;7(6):583–7. [PubMed: 42593]
    153.
    Roth TG, Roehrs TA, Koshorek GL. et al. Hypnotic effects of low doses of quazepam in older insomniacs. J Clin Psychopharmacol. 1997;17(5):401–6. [PubMed: 9315991]
    154.
    Roth T, Ancoli-Israel S. Daytime consequences and correlates of insomnia in the United States: Results of the 1991 National Sleep Foundation Survey. II. Sleep. 1999;22(Suppl 2):S354–8. [PubMed: 10394607]
    155.
    Sabbatini M, Minale B, Crispo A. et al. Insomnia in maintenance haemodialysis patients. Nephrol Dial Transplant. 2002;17(5):852–6. [PubMed: 11981073]
    156.
    Saletu-Zhylarz G, Saletu B, Anderer P. et al. Nonorganic insomnia in generalized anxiety disorder. Neuropsychobiol. 1997;36(3):117–29. [PubMed: 9313244]
    157.
    Saletu-Zyhlarz G, Anderer P, Gruber G. et al. Insomnia Related to Postmenopausal Syndrome and Hormone Replacement Therapy: Sleep Laboratory Studies on Baseline Differences Between Patients and Controls and Double-Blind, Placebo-Controlled Investigations on the Effects of a Novel Estrogen-Progestogen Combination (Climodien (R), Lafamme (R)) Versus Estrogen Alone. J Sleep Res. 2003;12(3):239–54. [PubMed: 12941063]
    158.
    Sanavio E, Vidotto G, Bettinardi O. et al. Behaviour therapy for DIMS: Comparison of three treatment procedures with follow-up. Behav Psychother. 1990;18(3):151–67.
    159.
    Sastre-y-Hernandez M, Visser P, Schutt B. et al. Sublingual lormetazepam in the treatment of sleep disorders in general practice patients. Hum Psychopharmacol. 1988;3(2):139–44.
    160.
    Savard J, Simard S, Blanchet J. et al. Prevalence, clinical characteristics, and risk factors for insomnia in the context of breast cancer. Sleep. 2001;24(5):583–90. [PubMed: 11480655]
    161.
    Scharf MB, Roth PB, Dominguez RA. et al. Estazolam and flurazepam: multicenter, placebo-controlled comparative study in outpatients with insomnia. J Clin Pharmacol. 1990;30:461–7. [PubMed: 1971831]
    162.
    Scharf MB, Roth T, Vogel GW. et al. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry. 1994;55(5):192–9. [PubMed: 8071269]
    163.
    Schneider-Helmert D. Twenty-four-hour sleep-wake function and personality patterns in chronic insomniacs and healthy controls. Sleep. 1987;10(5):452–62. [PubMed: 3685753]
    164.
    Seidel WF, Ball S, Cohen S. et al. Daytime alertness in relation to mood, performance, and nocturnal sleep in chronic insomniacs and noncomplaining sleepers. Sleep. 1984;7(3):230–8. [PubMed: 6484427]
    165.
    Sharpley AL, Attenburrow ME, Cowen PJ. Assessment and treatment of insomnia (including a case control study of patients with Primary Insomnia). Int J Psychiatry Clin Pract. 1997;1(2):107–17. [PubMed: 24936665]
    166.
    Shaver JL, Johnston SK, Lentz MJ. et al. Stress exposure, psychological distress, and physiological stress activation in midlife women with insomnia. Psychosom Med. 2002;64(5):793–802. [PubMed: 12271110]
    167.
    Shaw SH, Curson H, Coquelin JP. A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients.[erratum appears in J Int Med Res 1992 Nov;20(6):following 494] J Int Med Res. 1992;20(2):150–61. [PubMed: 1521671]
    168.
    Shealy R. The effectiveness of various treatment techniques on different degrees and durations of sleep onset insomnia. Behav Res Ther. 1979;17(6):541–6. [PubMed: 393245]
    169.
    Shochat T, Umphress J, Israel AG. et al. Insomnia in primary care patients. Sleep. 1999;22(Suppl 2):S359–65. [PubMed: 10394608]
    170.
    Stanton HE. Hypnotic relaxation and the reduction of sleep onset insomnia. Int J Psychosom. 1989;36(14):64–8. [PubMed: 2689375]
    171.
    Steens RD, Pouliot Z, Millar TW. et al. Effects of zolpidem and triazolam on sleep and respiration in mild to moderate chronic obstructive pulmonary disease. Sleep. 1993;16(4):318–26. [PubMed: 8341892]
    172.
    Stip E, Furlan M, Lussier I. et al. Double-blind, placebo-controlled study comparing effects of zopiclone and temazepam on cognitive functioning of insomniacs. Hum Psychopharmacol. 1999;14(4):253–61.
    173.
    Sugerman JL, Stern JA, Walsh JK. Daytime alertness in subjective and objective insomnia: some preliminary findings. Biol Psychiatry. 1985;20(7):741–50. [PubMed: 4005333]
    174.
    Taylor DJ. A cross-sectional analysis of depression, anxiety, and insomnia [dissertation]. Memphis (TN): University of Memphis; 2003.
    175.
    Terzano MG, Parrino L, Cirignotta F. et al. Studio Morfeo: insomnia in primary care, a survey conducted on the Italian population. Sleep Med. 2004;5(1):67–75. [PubMed: 14725829]
    176.
    Tietz EI, Roth T, Zorick FJ. et al. The acute effect of quazepam on the sleep of chronic insomniacs. A dose-response study. Arzneimittel- orschung. 1981;31(11):1963–6. [PubMed: 6119098]
    177.
    Tuk B, Oberye JJ, Pieters MS. et al. Pharmacodynamics of temazepam in primary insomnia: assessment of the value of quantitative electroencephalography and saccadic eye movements in predicting improvement of sleep. Clin Pharmacol Ther. 1997;62:444–52. [PubMed: 9357396]
    178.
    Vallieres A, Morin CM, Guay B. et al. Sequential treatment for chronic insomnia: A pilot study. [References] Behav Sleep Med. 2004;2(2):94–112. [PubMed: 15600227]
    179.
    Vgontzas AN, Kales A, Bixler EO. et al. Usefulness of polysomnographic studies in the differential diagnosis of insomnia. Int J Neurosci. 1995;82(12):47–60. [PubMed: 7591515]
    180.
    Vignola A, Lamoureux C, Bastien CH. et al. Effects of chronic insomnia and use of benzodiazepines on daytime performance in older adults. J Gerontol Series B Psychol Sci Soc Sci. 2000;55(1):P54–62. [PubMed: 10728124]
    181.
    Vincent NK, Walker JR. Perfectionism and chronic insomnia. J Psychosom Res. 2000;49(5):349–54. [PubMed: 11164059]
    182.
    Viukari M, Jaatinen P, Kylmamaa T. Flunitrazepam and nitrazepam as hypnotics in psychogeriatric inpatients. Clin Ther. 1983;5(6):662–70. [PubMed: 6627292]
    183.
    Walsh JK. Zolpidem “as Needed” for the Treatment of Primary Insomnia: a Double-Blind, Placebo-Controlled Study. Sleep Med Rev. 2002;6:S7–11. [PubMed: 12607571]
    184.
    Walsh JK, Fry J, Erwin CW. et al. Efficacy and tolerability of 14-day administration of zaleplon 5 mg and 10 mg for the treatment of primary insomnia. Clin Drug Invest. 1998;16:347–54.
    185.
    Walsh JK, Fry J, Richardson GS. et al. Short term efficacy of zaleplon in older patients with chronic insomnia. Clin Drug Invest. 2000;20:143–9.
    186.
    Walsh JK, Targum SD, Pegram V. et al. Multicenter clinical investigation of estazolam: short term efficacy. Curr Ther Res. 1984;36:866–74.
    187.
    Walsh JK, Erman M, Erwin CW. et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia. Hum Psychopharmacol. 1998;13(3):191–8.
    188.
    Walsh JK, Roth T, Randazzo A. et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep. 2000;23(8):1087–96. [PubMed: 11145323]
    189.
    Wang RIH, Stockdale SL. Subjective and objective method assessing the efficacy of hypnotic medications in insomniacs. J Clin Pharmacol. 1977;17:728–33. [PubMed: 336652]
    190.
    Wang W, Zhu SZ, Pan LC. et al. Mismatch negativity and personality traits in chronic primary insomniacs. Funct Neurol. 2001;16(1):3–10. [PubMed: 11396269]
    191.
    Waters WF, Hurry MJ, Binks PG. et al. Behavioral and hypnotic treatments for insomnia subtypes. Behav Sleep Med. 2003;1(2):81–101. [PubMed: 15600131]
    192.
    Winsauer HJ, O'Hair DE, Valero R. Quazepam: short term treatment of insomnia in geriatric outpatients. Curr Ther Res. 1984;35:228–34.
    193.
    Yeo BK, Perera IS, Kok LP. et al. Insomnia in the community. Singapore Med J. 1996;37(3):282–4. [PubMed: 8942230]
    194.
    Zammit GK, Weiner J, Damato N. et al. Quality of life in people with insomnia. Sleep. 1999;22(Suppl 2):S379–85. [PubMed: 10394611]
    195.
    Zhdanova IV, Wurtman RJa, Regan MM. et al. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab. 2001;86(10):4727–30. [PubMed: 11600532]

Views

  • PubReader
  • Print View
  • Cite this Page

Other titles in these collections

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...